FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912325088> ?p ?o ?g. }

• W2912325088 endingPage "315" @default.
• W2912325088 startingPage "309" @default.
• W2912325088 abstract "Abstract Introduction Co‐administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti‐Xa activity when measuring direct oral anticoagulant (DOAC) levels. We aimed to evaluate in vitro the degree of the interference of increasing enoxaparin concentrations on xaban plasma levels measured by different chromogenic anti‐Xa assays with drug‐specific calibrators and controls. Methods Seven plasma samples were spiked with apixaban, edoxaban, or rivaroxaban at fixed concentration, and enoxaparin at increasing concentrations (0, 0.125, 0.250, 0.50, 1.0, 1.50, and 2.0 IU/mL). The evaluated chromogenic assays were as follows: Biophen DiXaI and Biophen Heparin LRT (Hyphen BioMed), Berichrom Heparin and Innovance Heparin (Siemens), STA‐Liquid Anti‐Xa (Stago Diagnostics), Technochrom anti‐Xa (Technoclone), and HemosIL Liquid Anti‐Xa (Werfen). Results The presence of enoxaparin caused increased DOAC levels, with over‐estimation depending on the anti‐Xa assay and on the heparin concentration in the sample. The smallest over‐estimation was in the sample with enoxaparin 0.125 IU/mL and the greatest in the sample with enoxaparin 2.0 IU/mL (0%, 3.1%, and 7.4% vs 583.8%, 526.1%, and 415.2% for apixaban, edoxaban, and rivaroxaban, respectively). Biophen DiXaI showed lower interference compared to other methods (maximum over‐estimation in the presence of enoxaparin 2.0 IU/mL: 56.4% dosing rivaroxaban by Biophen DIXaI vs 583.8% dosing apixaban by Berichrom Heparin). Conclusion The presence of enoxaparin interferes with xabans measurement by chromogenic anti‐Xa assays causing falsely elevated DOAC levels, the over‐estimation being dependent on the anti‐Xa assay and on the heparin concentration in the sample." @default.
• W2912325088 created "2019-02-21" @default.
• W2912325088 creator A5008150148 @default.
• W2912325088 creator A5028671796 @default.
• W2912325088 creator A5032555810 @default.
• W2912325088 creator A5043870217 @default.
• W2912325088 creator A5054455430 @default.
• W2912325088 creator A5058256497 @default.
• W2912325088 date "2019-01-30" @default.
• W2912325088 modified "2023-09-26" @default.
• W2912325088 title "An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays" @default.
• W2912325088 cites W1577484948 @default.
• W2912325088 cites W1839975480 @default.
• W2912325088 cites W1913182214 @default.
• W2912325088 cites W1944798274 @default.
• W2912325088 cites W1965320794 @default.
• W2912325088 cites W2082987265 @default.
• W2912325088 cites W2084643544 @default.
• W2912325088 cites W2085073510 @default.
• W2912325088 cites W2096246254 @default.
• W2912325088 cites W2098837786 @default.
• W2912325088 cites W2103247642 @default.
• W2912325088 cites W2115787552 @default.
• W2912325088 cites W2118092611 @default.
• W2912325088 cites W2134427191 @default.
• W2912325088 cites W2136489990 @default.
• W2912325088 cites W2149388786 @default.
• W2912325088 cites W2158014557 @default.
• W2912325088 cites W2160625453 @default.
• W2912325088 cites W2166402206 @default.
• W2912325088 cites W2194419520 @default.
• W2912325088 cites W2548076162 @default.
• W2912325088 cites W2560791129 @default.
• W2912325088 cites W2616237281 @default.
• W2912325088 cites W2738356922 @default.
• W2912325088 cites W2738394031 @default.
• W2912325088 cites W2800785414 @default.
• W2912325088 cites W2801340189 @default.
• W2912325088 doi "https://doi.org/10.1111/ijlh.12974" @default.
• W2912325088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6850445" @default.
• W2912325088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30698331" @default.
• W2912325088 hasPublicationYear "2019" @default.
• W2912325088 type Work @default.
• W2912325088 sameAs 2912325088 @default.
• W2912325088 citedByCount "5" @default.
• W2912325088 countsByYear W29123250882020 @default.
• W2912325088 countsByYear W29123250882021 @default.
• W2912325088 countsByYear W29123250882022 @default.
• W2912325088 crossrefType "journal-article" @default.
• W2912325088 hasAuthorship W2912325088A5008150148 @default.
• W2912325088 hasAuthorship W2912325088A5028671796 @default.
• W2912325088 hasAuthorship W2912325088A5032555810 @default.
• W2912325088 hasAuthorship W2912325088A5043870217 @default.
• W2912325088 hasAuthorship W2912325088A5054455430 @default.
• W2912325088 hasAuthorship W2912325088A5058256497 @default.
• W2912325088 hasBestOaLocation W29123250881 @default.
• W2912325088 hasConcept C126322002 @default.
• W2912325088 hasConcept C128463046 @default.
• W2912325088 hasConcept C185592680 @default.
• W2912325088 hasConcept C2776301958 @default.
• W2912325088 hasConcept C2776884760 @default.
• W2912325088 hasConcept C2777288759 @default.
• W2912325088 hasConcept C2777557582 @default.
• W2912325088 hasConcept C2778205648 @default.
• W2912325088 hasConcept C2778661090 @default.
• W2912325088 hasConcept C2778825682 @default.
• W2912325088 hasConcept C2779161974 @default.
• W2912325088 hasConcept C2780290652 @default.
• W2912325088 hasConcept C2780638905 @default.
• W2912325088 hasConcept C43617362 @default.
• W2912325088 hasConcept C71924100 @default.
• W2912325088 hasConcept C98274493 @default.
• W2912325088 hasConceptScore W2912325088C126322002 @default.
• W2912325088 hasConceptScore W2912325088C128463046 @default.
• W2912325088 hasConceptScore W2912325088C185592680 @default.
• W2912325088 hasConceptScore W2912325088C2776301958 @default.
• W2912325088 hasConceptScore W2912325088C2776884760 @default.
• W2912325088 hasConceptScore W2912325088C2777288759 @default.
• W2912325088 hasConceptScore W2912325088C2777557582 @default.
• W2912325088 hasConceptScore W2912325088C2778205648 @default.
• W2912325088 hasConceptScore W2912325088C2778661090 @default.
• W2912325088 hasConceptScore W2912325088C2778825682 @default.
• W2912325088 hasConceptScore W2912325088C2779161974 @default.
• W2912325088 hasConceptScore W2912325088C2780290652 @default.
• W2912325088 hasConceptScore W2912325088C2780638905 @default.
• W2912325088 hasConceptScore W2912325088C43617362 @default.
• W2912325088 hasConceptScore W2912325088C71924100 @default.
• W2912325088 hasConceptScore W2912325088C98274493 @default.
• W2912325088 hasIssue "3" @default.
• W2912325088 hasLocation W29123250881 @default.
• W2912325088 hasLocation W29123250882 @default.
• W2912325088 hasLocation W29123250883 @default.
• W2912325088 hasOpenAccess W2912325088 @default.
• W2912325088 hasPrimaryLocation W29123250881 @default.
• W2912325088 hasRelatedWork W1997499869 @default.
• W2912325088 hasRelatedWork W2520740086 @default.
• W2912325088 hasRelatedWork W2920555099 @default.
• W2912325088 hasRelatedWork W3006492431 @default.

• next